{
  "id": 4813788,
  "title": "JPMorgan initiates BlossomHill Therapeutics stock with overweight",
  "url": "https://urgent.news/2026/09/01/jpmorgan-initiates-blossomhill-therapeutics-stock-with-overweight",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-01T07:30:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-initiates-blossomhill-therapeutics-stock-with-overweight-93CH-4883560"
  },
  "original_language": "en",
  "account": "JPMorgan has started coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with an Overweight rating and a price target of $28.00. BlossomHill is a clinical-stage oncology company focused on developing therapeutics with unique structural attributes. Their lead product, BH-30643, is a macrocyclic EGFR inhibitor. The company has a market capitalization of $561 million and a current stock price of $18.30, resulting in a 14% return over the past six months. Despite being deemed overvalued according to InvestingPro analysis, BlossomHill has a strong balance sheet with more cash than debt and a robust current ratio of 7.4. JPMorgan analyst Brian Cheng projects a December 2027 price target of $28. The firm highlights the rising prevalence of resistance mutations, such as C797S, in EGFRm NSCLC, suggesting potential for BH-30643 to expand into other adjacent EGFRm segments. BlossomHill is also developing a clinical-stage CLK inhibitor for liquid tumors and a preclinical pan-KRAS program. Recently, the company completed its initial public offering, raising $150 million, which provides additional capital for future developments.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}